Physician profile
Veronica Spanjol
NPI 1982292983
$2,271.90
in general payments reported to CMS, 2019-2025
22 companies · $1,277 in 2025
The $1,277 reported for 2025 was more than what 85% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $176 · 2022: $11.66 · 2023: $549 · 2024: $257 · 2025: $1,277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,084.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,083.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $272.85 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $223.45 | 2023-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Lundbeck LLC | $219.26 | 2023-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $204.27 | 2024-2025 | Cobenfy |
| Corium, LLC | $199.34 | 2023-2025 | Azstarys |
| Abbvie INC. | $170.10 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $136.59 | 2025 | Fanapt, Hetlioz |
| Tris Pharma INC | $134.12 | 2021-2025 | Dyanavel Xr |
| Neurocrine Biosciences, INC. | $129.03 | 2023-2025 | Ingrezza |
| Alkermes, INC. | $125.27 | 2023-2025 | Lybalvi, Aristada, Vivitrol |
| Axsome Therapeutics, INC. | $101.47 | 2023-2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $67.16 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $64.76 | 2021-2025 | Trintellix |
| Almatica Pharma LLC | $60.12 | 2024-2025 | Loreev Xr |
| Teva Pharmaceuticals USA, INC. | $36.17 | 2025 | Austedo Xr |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $21.40 | 2025 | |
| Bausch Health US, LLC | $21.22 | 2023 | Wellbutrin, Aplenzin |
| Janssen Pharmaceuticals, INC | $20.09 | 2021 | |
| Avion Pharmaceuticals | $19.49 | 2023 | Methylphenidate Hydrochloride |
| Collegium Pharmaceutical, INC. | $18.35 | 2025 | Jornay Pm |
| Sage Therapeutics, LLC | $13.76 | 2025 | Zurzuvae |
| Eisai INC. | $13.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Spanjol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.